Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Toast (NYSE: TOST), the digital technology platform built for hospitality, today announced an agreement with Dine Brands Global, Inc. (NYSE: DIN), the parent company of Applebee's Neighborhood Grill + ...

A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with scientists from the Albert ...

A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, ...

Trontinemab reduced amyloid levels below the 24 centiloid threshold in 81% of participants (n=21/26) in the 3.6 mg/kg dose group ... Brainshuttletm bispecific #2+1 amyloid-beta antibody specifically ...

6): the C-terminal RING-box, which recruits a specific E2 enzyme (UbcH7) and the N-terminal Ubl domain required for recognition of target protein, designated ‘X’, for ubiquitination before ...

Fibrinogen binding to N-terminal domain (NTD) of spike: To protect the more conserved NTD, the virus interacts with fibrinogen, protecting the NTD region from antibody recognition. This dual strategy ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...